Reduction in ANCA levels associated with mepolizumab add-on treatment in eosinophilic granulomatosis with polyangiitis: Case series and literature review

Allergol Int. 2024 Jan;73(1):180-183. doi: 10.1016/j.alit.2023.09.001. Epub 2023 Oct 16.

Authors

Yosuke Kamide¹, Kentaro Watai², Yuto Nakamura³, Maki Iwata³, Yuma Fukutomi³, Masami Taniguchi², Kiyoshi Sekiya³

Affiliations

¹ Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan. Electronic address: m08702012@gunma-u.ac.jp.
² Center for Immunology and Allergology, Shonan Kamakura General Hospital, Kanagawa, Japan.
³ Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.

PMID: 37852914
DOI: 10.1016/j.alit.2023.09.001

No abstract available

Publication types

Review
Letter

MeSH terms

Antibodies, Antineutrophil Cytoplasmic
Antibodies, Monoclonal, Humanized / therapeutic use
Churg-Strauss Syndrome* / diagnosis
Churg-Strauss Syndrome* / drug therapy
Granulomatosis with Polyangiitis* / diagnosis
Granulomatosis with Polyangiitis* / drug therapy
Humans

Substances

mepolizumab
Antibodies, Antineutrophil Cytoplasmic
Antibodies, Monoclonal, Humanized